Amb a 1 isoforms: Unequal siblings with distinct immunological features

• DOI: 10.1111/all.13196
• Publication Date: 2017-05-02T16:55:08Z
• Authors: M. Wolf; T. E. Twaroch; S. Huber; M. Reithofer; M. Steiner; L. Aglas; M. Hauser; I. Aloisi; C. Asam; H. Hofer; M. A. Parigiani; C. Ebner; B. Bohle; P. Briza; A. Neubauer; F. Stolz; B. Jahn‐Schmid; M. Wallner; F. Ferreira
• Keywords: Plant Extracts; Immune Sera; Siblings; T-Lymphocytes; Rhinitis, Allergic, Seasonal; Allergens; Antigens, Plant; Cross Reactions; Immunoglobulin E; Disease Models, Animal; Mice; 03 medical and health sciences; Phenotype; 0302 clinical medicine; Immunoglobulin G; Animals; Humans; Protein Isoforms; Female; ORIGINAL ARTICLES; Ambrosia; allergenicity; Amb a 1 allergen; cross-reactivity; immunogenicity; ragweed pollen allergy; Immunology and Allergy; Immunology; Plant Proteins

Ragweed pollen represents a major allergy risk factor. extracts contain five different isoforms of the allergen Amb 1. However, immunological characteristics 1 are not fully investigated. Here, we compared physicochemical and properties three most important isoforms.After purification, were physicochemically characterized, tested for antibody binding induction human T-cell proliferative responses. Their further evaluated in vitro vivo mouse model.Amb exhibited distinct patterns IgE immunogenicity. Compared to 1.02 or 03 isoforms, 1.01 showed higher IgE-binding activity. Isoforms 01 potent stimulators patients' T cells. In model immunization, induced levels IgG antibodies when 02 03. Interestingly, ragweed-sensitized patients also displayed an response isoforms. unlike therapy-induced antibodies, sensitization-induced did show IgE-blocking activity.The present study that naturally occurring possess immunogenic sensitizing properties. These findings should be considered selecting sequences molecule-based diagnosis therapy ragweed allergy. Due its high activity, isoform included diagnostic tests. contrast, due their limited B- cross-reactivity patterns, combination might more attractive strategy immunotherapy.